5-Amino-1MQ vs SLU-PP-332
preclinical vs Emerging
compatible Distinct mechanisms (ERR agonism vs NNMT inhibition) likely complementary without known interactions.
Molecular Data
5-Amino-1MQ SLU-PP-332
Weight — 290.32 Da
Half-life 4-7 hours (3.8h IV, 6.9h oral) Under investigation (no human PK data)
Chain — Non-peptide small molecule
Type Small molecule NNMT enzyme inhibitor Synthetic ERR agonist
Key Benefits
5-Amino-1MQ
01 Enhanced NAD+ levels
02 Improved mitochondrial function
03 Better energy metabolism
04 Enhanced cellular repair
05 Improved insulin sensitivity
06 Longevity support
07 Convenient daily oral dosing
SLU-PP-332
01 Exercise mimetic effects without physical activity
02 12% weight loss in 28 days
03 70% increased endurance
04 25% enhanced fatty acid oxidation
05 Improved insulin sensitivity
06 Reduced hepatic steatosis
07 Cardiac protection
08 Reversal of age-related mitochondrial dysfunction
Dosing Protocols
5-Amino-1MQ
50-100mg oral or 150-500mcg SubQ / Once daily, preferably morning
Conservative starting (mcg protocol) 150-250mcg 1x daily
Conservative standard (mcg protocol) 250-500mcg 1x daily
Study-based (mg protocol) ~350mg (5mg/kg) 1x daily
SLU-PP-332
NO HUMAN DOSE ESTABLISHED (animal studies: 50 mg/kg IP) / Research only - not approved for human use
Standard Metabolic Protocol 50 mg/kg (animal dosing) Twice daily
Acute Exercise Enhancement 50 mg/kg (animal dosing) Single dose 1 hour pre-exercise
Extended Treatment 50 mg/kg (animal dosing) Twice daily for 4-8 weeks
Side Effects
5-Amino-1MQ
Generally minimal side effects
Occasional mild GI adjustment
Potential sleep interference if dosed late in day
SLU-PP-332
Animal studies show favorable safety with no severe effects at therapeutic doses
Well-tolerated in rodents and canines
No liver, kidney, or cardiac toxicity documented
No lean mass loss
Does not suppress hormones or act as stimulant
Minor plasma cholesterol and liver enzyme changes in some studies
Contraindications
Pregnancy or breastfeeding
Pre-existing metabolic conditions (consult healthcare provider)
NOT FOR HUMAN USE - no approved human dose
No human clinical trials conducted
Potential interaction with diabetes medications
Research Evidence
5-Amino-1MQ SLU-PP-332
Status preclinical Emerging
References 3 studies 4 studies
Latest March 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.